309 related articles for article (PubMed ID: 29075615)
21. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
22. Targeting epigenetic programs in MLL-rearranged leukemias.
Bernt KM; Armstrong SA
Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
[TBL] [Abstract][Full Text] [Related]
23. Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles.
Yang XH; Wang B; Cunningham JM
BMC Med Genomics; 2015; 8 Suppl 2(Suppl 2):S6. PubMed ID: 26043758
[TBL] [Abstract][Full Text] [Related]
24. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
[TBL] [Abstract][Full Text] [Related]
25. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
26. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
[TBL] [Abstract][Full Text] [Related]
27. [Epigenetic therapy for hematologic malignancies].
Kobayashi Y
Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
[TBL] [Abstract][Full Text] [Related]
28. Chromatin Complexes Maintain Self-Renewal of Myeloid Progenitors in AML: Opportunities for Therapeutic Intervention.
Uckelmann HJ; Armstrong SA
Stem Cell Reports; 2020 Jul; 15(1):6-12. PubMed ID: 32559456
[TBL] [Abstract][Full Text] [Related]
29. Recurrent
Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).
Tanaka M; Roberts JM; Qi J; Bradner JE
Pharm Pat Anal; 2015; 4(4):261-84. PubMed ID: 26174566
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukemia with DNMT3A mutations.
Li Y; Zhu B
Leuk Lymphoma; 2014 Sep; 55(9):2002-12. PubMed ID: 24283755
[TBL] [Abstract][Full Text] [Related]
32. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
Riedel SS; Haladyna JN; Bezzant M; Stevens B; Pollyea DA; Sinha AU; Armstrong SA; Wei Q; Pollock RM; Daigle SR; Jordan CT; Ernst P; Neff T; Bernt KM
J Clin Invest; 2016 Apr; 126(4):1438-50. PubMed ID: 26927674
[TBL] [Abstract][Full Text] [Related]
33. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
McDevitt MA
Semin Oncol; 2012 Feb; 39(1):109-22. PubMed ID: 22289497
[TBL] [Abstract][Full Text] [Related]
34. Insights into novel emerging epigenetic drugs in myeloid malignancies.
Chandhok NS; Prebet T
Ther Adv Hematol; 2019; 10():2040620719866081. PubMed ID: 31431820
[TBL] [Abstract][Full Text] [Related]
35. Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications.
Yang X; Wong MPM; Ng RK
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527484
[TBL] [Abstract][Full Text] [Related]
36. DNA methylation as a pathogenic event and as a therapeutic target in AML.
Schoofs T; Müller-Tidow C
Cancer Treat Rev; 2011; 37 Suppl 1():S13-8. PubMed ID: 21612874
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects.
Gambacorta V; Gnani D; Vago L; Di Micco R
Front Cell Dev Biol; 2019; 7():207. PubMed ID: 31681756
[TBL] [Abstract][Full Text] [Related]
38. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
[TBL] [Abstract][Full Text] [Related]
39. Role of epigenetic in leukemia: From mechanism to therapy.
Liu XL; Liu HQ; Li J; Mao CY; He JT; Zhao X
Chem Biol Interact; 2020 Feb; 317():108963. PubMed ID: 31978391
[TBL] [Abstract][Full Text] [Related]
40. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]